Tianjin Medical Journal ›› 2024, Vol. 52 ›› Issue (2): 148-153.doi: 10.11958/20230416
• Experimental Research • Previous Articles Next Articles
WANG Shoufan(), XU Yihou, XU Aiqin, ZHU Lihong
Received:
2023-04-11
Revised:
2023-05-10
Published:
2024-02-15
Online:
2024-01-26
WANG Shoufan, XU Yihou, XU Aiqin, ZHU Lihong. Effect of baicalin regulating cAMP/PKA/CREB signaling pathway on skin barrier function in eczema rats[J]. Tianjin Medical Journal, 2024, 52(2): 148-153.
CLC Number:
组别 | EASI评分/分 | TEWL/ (g·m-2·h-1) | WCSC/% |
---|---|---|---|
NC组 | 0 | 8.68±0.37 | 63.57±3.11 |
Model组 | 7.33±0.32a | 46.52±1.89a | 18.86±0.82a |
BA-L组 | 6.84±0.15b | 40.14±1.57b | 25.57±1.13b |
BA-M组 | 6.11±0.10bc | 32.28±1.23bc | 34.43±1.66bc |
BA-H组 | 3.32±0.09bcd | 17.73±0.82bcd | 46.68±2.23bcd |
PNS组 | 3.30±0.10bcd | 17.69±0.75bcd | 46.73±2.19bcd |
BA-H+SQ22536组 | 6.58±0.12e | 35.52±1.63e | 30.36±1.47e |
BA-H+H-89组 | 6.54±0.11e | 35.48±1.57e | 30.45±1.45e |
F | 3 384.000* | 1 139.000* | 698.800* |
Tab.1 Comparison of EASI score, TEWL and WCSC in lesion area of back between eight groups
组别 | EASI评分/分 | TEWL/ (g·m-2·h-1) | WCSC/% |
---|---|---|---|
NC组 | 0 | 8.68±0.37 | 63.57±3.11 |
Model组 | 7.33±0.32a | 46.52±1.89a | 18.86±0.82a |
BA-L组 | 6.84±0.15b | 40.14±1.57b | 25.57±1.13b |
BA-M组 | 6.11±0.10bc | 32.28±1.23bc | 34.43±1.66bc |
BA-H组 | 3.32±0.09bcd | 17.73±0.82bcd | 46.68±2.23bcd |
PNS组 | 3.30±0.10bcd | 17.69±0.75bcd | 46.73±2.19bcd |
BA-H+SQ22536组 | 6.58±0.12e | 35.52±1.63e | 30.36±1.47e |
BA-H+H-89组 | 6.54±0.11e | 35.48±1.57e | 30.45±1.45e |
F | 3 384.000* | 1 139.000* | 698.800* |
组别 | IgE/(mg/L) | IFN-γ/(ng/L) | IL-4/(ng/L) |
---|---|---|---|
NC组 | 112.28±5.44 | 63.32±2.79 | 38.67±1.73 |
Model组 | 283.36±12.25a | 24.42±1.13a | 84.45±3.83a |
BA-L组 | 243.43±10.20b | 33.58±1.42b | 72.29±2.97b |
BA-M组 | 200.12±8.45bc | 42.28±1.87bc | 61.33±2.41bc |
BA-H组 | 134.66±5.45bcd | 54.47±2.05bcd | 46.67±1.72bcd |
PNS组 | 132.28±5.61bcd | 54.36±1.98bcd | 47.72±1.66bcd |
BA-H+SQ22536组 | 223.37±10.54e | 35.57±1.62e | 68.87±2.69e |
BA-H+H-89组 | 220.69±10.31e | 35.63±1.59e | 69.03±2.58e |
F | 563.800* | 599.500* | 445.000* |
Tab.2 Comparison of serum IgE, IFN-γ and IL-4 levels between eight groups of rats
组别 | IgE/(mg/L) | IFN-γ/(ng/L) | IL-4/(ng/L) |
---|---|---|---|
NC组 | 112.28±5.44 | 63.32±2.79 | 38.67±1.73 |
Model组 | 283.36±12.25a | 24.42±1.13a | 84.45±3.83a |
BA-L组 | 243.43±10.20b | 33.58±1.42b | 72.29±2.97b |
BA-M组 | 200.12±8.45bc | 42.28±1.87bc | 61.33±2.41bc |
BA-H组 | 134.66±5.45bcd | 54.47±2.05bcd | 46.67±1.72bcd |
PNS组 | 132.28±5.61bcd | 54.36±1.98bcd | 47.72±1.66bcd |
BA-H+SQ22536组 | 223.37±10.54e | 35.57±1.62e | 68.87±2.69e |
BA-H+H-89组 | 220.69±10.31e | 35.63±1.59e | 69.03±2.58e |
F | 563.800* | 599.500* | 445.000* |
组别 | cAMP/(nmol/L) | AQP3/β-actin | CRAMP/β-actin | p-PKA/PKA | p-CREB/CREB |
---|---|---|---|---|---|
NC组 | 13.36±0.54 | 1.56±0.12 | 1.68±0.13 | 0.94±0.03 | 0.92±0.08 |
Model组 | 4.67±0.23a | 0.42±0.03a | 0.72±0.05a | 0.23±0.02a | 0.41±0.03a |
BA-L组 | 5.89±0.26b | 0.59±0.05b | 0.93±0.07b | 0.36±0.02b | 0.52±0.04b |
BA-M组 | 7.34±0.28bc | 0.82±0.07bc | 1.14±0.11bc | 0.49±0.05bc | 0.60±0.05bc |
BA-H组 | 11.32±0.43bcd | 1.28±0.11bcd | 1.36±0.12bcd | 0.82±0.07bcd | 0.84±0.08bcd |
PNS组 | 11.36±0.45bcd | 1.30±0.12bcd | 1.38±0.13bcd | 0.84±0.07bcd | 0.86±0.07bcd |
BA-H+SQ22536组 | 6.64±0.37e | 0.73±0.06e | 1.03±0.09e | 0.42±0.03e | 0.54±0.04e |
BA-H+H-89组 | 11.40±0.41 | 0.75±0.06e | 1.06±0.11e | 0.44±0.03e | 0.56±0.05e |
F | 420.100* | 135.700* | 49.350* | 207.300* | 63.960* |
Tab.3 Comparison of protein levels of AQP3, CRAMP, cAMP, p-PKA and p-CREB in skin lesions between eight groups of rats
组别 | cAMP/(nmol/L) | AQP3/β-actin | CRAMP/β-actin | p-PKA/PKA | p-CREB/CREB |
---|---|---|---|---|---|
NC组 | 13.36±0.54 | 1.56±0.12 | 1.68±0.13 | 0.94±0.03 | 0.92±0.08 |
Model组 | 4.67±0.23a | 0.42±0.03a | 0.72±0.05a | 0.23±0.02a | 0.41±0.03a |
BA-L组 | 5.89±0.26b | 0.59±0.05b | 0.93±0.07b | 0.36±0.02b | 0.52±0.04b |
BA-M组 | 7.34±0.28bc | 0.82±0.07bc | 1.14±0.11bc | 0.49±0.05bc | 0.60±0.05bc |
BA-H组 | 11.32±0.43bcd | 1.28±0.11bcd | 1.36±0.12bcd | 0.82±0.07bcd | 0.84±0.08bcd |
PNS组 | 11.36±0.45bcd | 1.30±0.12bcd | 1.38±0.13bcd | 0.84±0.07bcd | 0.86±0.07bcd |
BA-H+SQ22536组 | 6.64±0.37e | 0.73±0.06e | 1.03±0.09e | 0.42±0.03e | 0.54±0.04e |
BA-H+H-89组 | 11.40±0.41 | 0.75±0.06e | 1.06±0.11e | 0.44±0.03e | 0.56±0.05e |
F | 420.100* | 135.700* | 49.350* | 207.300* | 63.960* |
[1] | BOYLE R J, SHAMJI M H. Aetiology and prevention of eczema[J]. Clin Exper Allergy, 2021, 51(3):380-381. doi:10.1111/cea.13626. |
[2] | GALL C. Causes and symptoms of atopic eczema[J]. J Allergy Ther, 2021, 12(3):1. |
[3] | 陈兴, 黄丽霞, 李忻红, 等. 中药外治湿疹用药规律的数据挖掘研究[J]. 辽宁中医杂志, 2021, 48(9):86-90. |
CHEN X, HUANG L X, LI X H, et al. Data mining research on the law of external treatment of eczema with traditional Chinese medicine[J]. Liaoning J Trad Chin Med, 2021, 48(9):86-90. doi:10.13192/j.issn.1000-1719.2021.09.023. | |
[4] | BOHANNON M, LIU M, NADEAU P, et al. Topical doxycycline monohydrate hydrogel 1% targeting proteases/PAR2 pathway is a novel therapeutic for atopic dermatitis[J]. Exp Dermatol, 2020, 29(12):1171-1175. doi:10.1111/exd.14201. |
[5] | 彭清, 孙柳, 苗雪圆, 等. 天然产物化合物作为肿瘤免疫调节剂的研究进展[J]. 中国中西医结合外科杂志, 2021, 27(1):136-140. |
PENG Q, SUN L, MIAO X Y, et al. Research progress of natural product compounds as tumor immunomodulators[J]. Chinese Journal of Surgery of Integrated Traditional and Western Medicine, 2021, 27(1):136-140. doi:10.3969/j.issn.1007-6948.2021.01.027. | |
[6] | WANG L, XIAN Y F, LOO S K F, et al. Baicalin ameliorates 2,4-dinitrochlorobenzene-induced atopic dermatitis-like skin lesions in mice through modulating skin barrier function,gut microbiota and JAK/STAT pathway[J]. Bioorg Chem, 2022, 119:105538. doi:10.1016/j.bioorg.2021.105538. |
[7] | TSAI Y F, CHEN C Y, LIN I W, et al. Imperatorin alleviates psoriasiform dermatitis by blocking neutrophil respiratory burst,adhesion,and chemotaxis through selective phosphodiesterase 4 inhibition[J]. Antioxid Redox Signal, 2021, 35(11):885-903. doi:10.1089/ars.2019.7835. |
[8] | 王永慧, 王思农, 肖静秋, 等. 藏药二十五味儿茶凝胶对大鼠慢性湿疹模型LTB-4、LTC-4因子的影响[J]. 中国皮肤性病学杂志, 2018, 32(5):568-570. |
WANG Y H, WANG S N, XIAO J Q, et al. Effects of Tibetan Drug Ershiwuweiercha Gel on factors ltb-4 and ltc-4 in model rats of chronic eczema[J]. Chin J Dermatology and Venereology, 2018, 32(5):568-570. doi:10.13735/j.cjdv.1001-7089.201711042. | |
[9] | FANG F, XIE Z, QUAN J, et al. Baicalin suppresses Propionibacterium acnes-induced skin inflammation by downregulating the NF-κB/MAPK signaling pathway and inhibiting activation of NLRP3 inflammasome[J]. Braz J Med Biol Res, 2020, 53(12):e9949. doi:10.1590/1414-431X20209949. |
[10] | 汪园园, 金明华, 黄颖娟, 等. 苓桂术甘汤联合热量限摄对湿疹模型大鼠皮损的影响及其机制分析[J]. 中国中西医结合杂志, 2020, 40(4):465-469. |
WANG Y Y, JIN M H, HUANG Y J, et al. Effect of calorie-restriction therapy combined Zhugan Decoction on eczema model rats[J]. Chinese Journal of Integrated Traditional and Western Medicine, 2020, 40(4):465-469. doi:10.7661/j.cjim.20190928.286. | |
[11] | 汪雪峰, 陈锋, 宋顺德, 等. 腺苷酸环化酶抑制剂和激动剂在脂多糖诱导的急性肺损伤中的作用[J]. 中国药理学通报, 2017, 33(10):1410-1414. |
WANG X F, CHEN F, SONG S D, et al. Effect of adenylate cyclase antagonists andagonist in acute lung injury induced by lipopolysaccharide[J]. Chinese Pharmacological Bulletin, 2017, 33(10):1410-1414. doi:10.3969/j.issn.1001-1978.2017.10.016. | |
[12] | 崇显瑾, 杨历新. 利拉鲁肽通过cAMP/PKA/CREB通路干预2型糖尿病大鼠骨质疏松的机制研究[J]. 中国病理生理杂志, 2021, 37(11):1949-1956. |
CHONG X J, YANG L X. Mechanism of liraglutide intervening osteoporosis in type 2 diabetic rats through cAMP/PKA/CREB signaling pathways[J]. Chinese Journal of Pathophysiology, 2021, 37(11):1949-1956. doi:10.3969/j.issn.1000-4718.2021.11.004. | |
[13] | AIERKEN K, LUO Y, MAIWULANJIANG M, et al. The suppressive effect of mamiran cream on atopic dermatitis-like skin lesions in vivo[J]. Evid Based Complement Alternat Med, 2021, 2021(1):2854238-2854249. doi:10.1155/2021/2854238. |
[14] | 汪秀梅, 武亦阁, 贺乙, 等. 针灸对湿热蕴肤型湿疹豚鼠皮肤屏障功能的影响[J]. 中国针灸, 2022, 42(7):779-784,810. |
WANG X M, WU Y G, HE Y, et al. Effect of acupuncture and moxibustion on skin barrier function in guinea pigs with eczema of skin damp-heat accumulation[J]. Chinese Journal of Acupuncture and Moxibustion, 2022, 42(7):779-784,810. doi:10.13703/j.0255-2930.20210619-k0001. | |
[15] | BOLLAG W B, AITKENS L, WHITE J, et al. Aquaporin-3 in the epidermis:more than skin deep[J]. Am J Physiol Cell Physiol, 2020, 318(6):C1144-C1153. doi:10.1152/ajpcell.00075.2020. |
[16] | 吴百威, 羊小华, 占润之. 甘草酸对特应性皮炎小鼠皮肤屏障功能的影响[J]. 中国临床药理学杂志, 2020, 36(10):1324-1327. |
WU B W, YANG X H, ZHAN R Z. Effects of glycyrrhizic acid on skin barrier function in mice with atopic dermatitis[J]. Chinese Journal of Clinical Pharmacology, 2020, 36(10):1324-1327. doi:10.13699/j.cnki.1001-6821.2020.10.042. | |
[17] | WANG X, XIE L, LONG J, et al. Therapeutic effect of baicalin on inflammatory bowel disease:A review[J]. J Ethnopharmacol, 2022, 283:114749. doi:10.1016/j.jep.2021.114749. |
[18] | SHERWANI M A, YANG K, JANI A, et al. Protective effect of baicalin against TLR4-mediated UVA-induced skin inflammation[J]. Photochem Photobiol, 2019, 95(2):605-611. doi:10.1111/php.13021. |
[19] | HUNG C H, WANG C N, CHENG H H, et al. Baicalin ameliorates imiquimod-induced psoriasis-like inflammation in mice[J]. Planta Med, 2018, 84(15):1110-1117. doi:10.1055/a-0622-8242. |
[20] | MA X, HAO M, ZHANG M H, et al. Integrated strategy of network analysis prediction and experimental validation to elucidate the possible mechanism of compound Turkish gall ointment in treating eczema[J]. Chin Med, 2022, 17:89-109. doi:10.1186/s13020-022-00643-2. |
[21] | WU J, GAN Y, LUO H, et al. β-Patchoulene ameliorates water transport and the mucus barrier in 5-fluorouracil-induced intestinal mucositis rats via the cAMP/PKA/CREB signaling pathway[J]. Front Pharmacol, 2021, 12:689491-689503. doi:10.3389/fphar.2021.689491. |
[22] | YUAN X H, YAO C, OH J H, et al. Vasoactive intestinal peptide stimulates melanogenesis in B16F10 mouse melanoma cells via CREB/MITF/tyrosinase signaling[J]. Biochem Biophys Res Commun, 2016, 477(3):336-342. doi:10.1016/j.bbrc.2016.06.105. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||